RA0685

antibody from Oursmab

Targeting: SIRPA BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0685

Provider

Oursmab

Product name

Anzurstobart (Biosimilar Reference Antibody) (SIRPA)

Antibody type

Monoclonal

Description

Anzurstobart is an investigational, fully human IgG4 monoclonal antibody that targets Signal Regulatory Protein Alpha (SIRP¦Á) with high affinity. It functions as a blocking antibody that specifically inhibits the interaction between SIRP¦Á on macrophages and its ligand CD47 on tumor cells. By disrupting this ¡°don't-eat-me¡± signaling axis, anzurstobart promotes macrophage-mediated phagocytosis of cancer cells. It is currently in clinical development (Phase I/II) for the treatment of various advanced solid tumors and hematologic malignancies, representing a novel strategy in cancer immunotherapy.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.